Bulletin
Investor Alert

New York Markets Open in:

Biogen Inc.

NAS: BIIB

GO
/marketstate/country/us

After Hours

/zigman2/quotes/201531540/composite

$

282.95

Change

+1.06 +0.38%

Volume

Volume 31,376

Nov 13, 2019, 7:21 p.m.

Quotes are delayed by 20 min

/zigman2/quotes/201531540/composite

Previous close

$ 291.40

$ 281.89

Change

-9.51 -3.26%

Day low

Day high

$280.95

$290.25

Open
Open: 290.25

52 week low

52 week high

$215.78

$344.00

Open

Market cap

$53.08B

Average volume

2.25M

P/E ratio

10.02

Rev. per Employee

$1.55M

EPS

28.12

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/biib

MarketWatch News on BIIB

  1. Buy Big Biotech — But Not Gilead, Analyst Says

    11:37 a.m. Nov. 12, 2019

    - Josh Nathan-Kazis

  2. Biogen ups investment in biosimilars

    8:20 a.m. Nov. 6, 2019

    - Jaimy Lee

  3. Biogen to book charge of about $65 mln once biosimilar deal closes

    7:52 a.m. Nov. 6, 2019

    - Ciara Linnane

  4. Biogen to buy biosimilar rights to Lucentis and Eylea, to pay $100 mln upfront

    7:51 a.m. Nov. 6, 2019

    - Ciara Linnane

  5. Biogen upgraded to outperform at Bernstein

    2:33 p.m. Oct. 30, 2019

    - Tomi Kilgore

  6. Biogen, Alkermes MS treatment Vumerity gets FDA approval

    7:33 a.m. Oct. 30, 2019

    - Tomi Kilgore

  7. Biogen upgraded to outperform from market perform at SVB Leerink

    8:23 a.m. Oct. 23, 2019

    - Tomi Kilgore

  8. Earnings Season Racks Up More Winners and Losers

    1:00 p.m. Oct. 22, 2019

    - Ben Walsh

  9. Biogen Stock Could Have Run Up Too Far on Alzheimer’s Drug Revival

    11:48 a.m. Oct. 22, 2019

    - Josh Nathan-Kazis

  10. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/biib

Other News on BIIB

  1. 3 of 2019’s Best New ETFs to Watch

    11:44 a.m. Nov. 13, 2019

    - InvestorPlace.com

  2. 6 Undervalued Stocks According to the Peter Lynch Value

    11:32 a.m. Nov. 13, 2019

    - GuruFocus.com

  3. Roche's SMA Drug Meets Primary Endpoint in Pivotal Study

    9:43 a.m. Nov. 12, 2019

    - Zacks.com

  4. Major Biotechs See Rising Tide in Short Interest

    9:31 a.m. Nov. 12, 2019

    - 247WallSt.com

  5. SunTrust sees 16% upside in Amgen in premarket analyst action

    9:12 a.m. Nov. 12, 2019

    - Seeking Alpha

  6. Roche's Gazyva successful in mid-stage lupus nephritis study

    10:06 a.m. Nov. 11, 2019

    - Seeking Alpha

  7. 4 Biotech Stocks That Could Keep Beating Wall Street

    9:28 a.m. Nov. 11, 2019

    - Zacks.com

  8. Sell Biogen Going Into Its Aducanumab BLA Filing

    2:05 p.m. Nov. 8, 2019

    - Seeking Alpha

  9. Pharma Sector Tops in October: Best ETFs & Stocks

    8:00 a.m. Nov. 8, 2019

    - Zacks.com

  10. Biogen Is A Buy Regardless Of Aducanumab

    3:15 p.m. Nov. 6, 2019

    - Seeking Alpha

  11. Biogen expands biosimilar relationship with Bioepis

    8:20 a.m. Nov. 6, 2019

    - Seeking Alpha

  12. Biotech ETFs in Focus on Impressive Q3 Earnings Results

    5:05 p.m. Nov. 4, 2019

    - Zacks.com

  13. Boston nonprofit playing big role in drug pricing

    1:43 p.m. Nov. 4, 2019

    - Seeking Alpha

  14. Boston nonprofit playing big role in drug pricing

    1:43 p.m. Nov. 4, 2019

    - Seeking Alpha

  15. Loading more headlines...
/news/pressrelease/company/us/biib

Press Releases on BIIB

  1. Alpha Synuclein Market Competitive Analysis With Growth Forecast Till 2025

    8:35 a.m. Nov. 8, 2019

    - Market Insight Reports

  2. Asuragen Announces Launch of AmplideX® PCR/CE SMN1/2 Plus Kit

    8:00 a.m. Nov. 6, 2019

    - BusinessWire - BZX

  3. Liver Fibrosis Drug Market Size, Status and Forecasts 2025

    10:56 p.m. Nov. 4, 2019

    - Market Insight Reports

  4. Loading more headlines...

Rates »

Link to MarketWatch's Slice.